Exact Sciences Corporation $EXAS Shares Purchased by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC boosted its holdings in Exact Sciences Corporation (NASDAQ:EXAS) by 50.0% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 34,188 shares of the medical research company’s stock after buying an additional 11,398 shares during the period. Nisa Investment Advisors LLC’s holdings in Exact Sciences were worth $3,472,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Westside Investment Management Inc. raised its stake in shares of Exact Sciences by 100.0% in the 3rd quarter. Westside Investment Management Inc. now owns 542 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 271 shares during the period. Quent Capital LLC purchased a new stake in Exact Sciences during the 3rd quarter worth $48,000. True Wealth Design LLC boosted its position in Exact Sciences by 61.7% during the 4th quarter. True Wealth Design LLC now owns 983 shares of the medical research company’s stock worth $100,000 after purchasing an additional 375 shares during the period. Bollard Group LLC acquired a new stake in Exact Sciences in the 3rd quarter valued at $55,000. Finally, OFI Invest Asset Management increased its holdings in Exact Sciences by 241.2% in the 3rd quarter. OFI Invest Asset Management now owns 1,085 shares of the medical research company’s stock valued at $59,000 after purchasing an additional 767 shares in the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on EXAS shares. Evercore set a $105.00 price objective on Exact Sciences and gave the stock an “in-line” rating in a research note on Monday, January 5th. Mizuho reiterated a “neutral” rating and issued a $105.00 target price (up from $85.00) on shares of Exact Sciences in a research note on Tuesday, January 20th. Zacks Research downgraded Exact Sciences from a “strong-buy” rating to a “hold” rating in a report on Friday, January 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Exact Sciences in a research report on Thursday, January 22nd. Finally, BTIG Research reaffirmed a “neutral” rating on shares of Exact Sciences in a research report on Tuesday, March 24th. Twenty-one analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and a consensus price target of $92.13.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $104.91 on Friday. The firm has a 50-day moving average of $103.52 and a two-hundred day moving average of $88.83. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.43 and a quick ratio of 2.17. The stock has a market cap of $20.03 billion, a P/E ratio of -95.37, a PEG ratio of 2.02 and a beta of 1.41. Exact Sciences Corporation has a 1-year low of $38.81 and a 1-year high of $104.98.

Exact Sciences (NASDAQ:EXAS) last announced its earnings results on Friday, February 13th. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.29). The business had revenue of $878.38 million for the quarter, compared to analysts’ expectations of $860.59 million. Exact Sciences had a positive return on equity of 0.53% and a negative net margin of 6.40%.The firm’s revenue was up 23.1% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.06) earnings per share. On average, research analysts expect that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation is a molecular diagnostics company headquartered in Madison, Wisconsin, dedicated to the early detection and prevention of cancer. The company’s flagship product, Cologuard®, is a noninvasive, stool-based DNA screening test for colorectal cancer that was developed in collaboration with the Mayo Clinic. By combining DNA mutation analysis with hemoglobin detection, Cologuard aims to improve screening adherence and identify cancers and precancerous lesions in average-risk adults.

Since its founding in 1995, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research and development.